Wall Street climbs on big pharma

Huge deals from Novartis and GSK help drive US markets sharply higher.

US stocks have closed sharply higher as investors welcomed news of more M&A action and solid earnings results from several big name firms.

At the closing bell, the Dow Jones Industrial Average jumped 64.99 points, or 0.40%, to 16,514.24.

The broad-based S&P 500 climbed 7.66 points, or 0.41%, to 1,879.55, while the tech-heavy Nasdaq Composite Index added 39.91 points, or 0.96%, to 4,161.46.

Strong quarterly reports from Netflix, Comcast and Lockheed Martin boosted optimism as earnings season gathered pace. Soft results from McDonald's represented a rare exception to the flow of good news.

General Motors and Apple are among the list of standout names to report later in the week.

Elsewhere, markets cheered news of deals worth close to $30 billion between pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly. The news was the latest sign of growing confidence in the marketplace.

The positive outlook was furthered by news Valeant Pharmaceuticals had made a $US45bn play for Botox-maker Allergan.

In economic data, existing home sales numbers in the US were weaker than expected, with high prices considered to have forced many buyers to the sidelines.

"Although today's session began on a quiet note, the key indices rallied after taking the lead from early strength in consumer discretionary ( 1.1%) and health care ( 1.5%) sectors," Briefing.com analyst Patrick O'Hare said.

"Given the early gains in two influential groups, the remainder of the market followed in somewhat reluctant fashion."

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles